These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 39066325)

  • 1. HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
    Chou TC; Maggirwar NS; Marsden MD
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finding a cure for HIV: will it ever be achievable?
    Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
    J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curing HIV: Pharmacologic approaches to target HIV-1 latency.
    Choudhary SK; Margolis DM
    Annu Rev Pharmacol Toxicol; 2011; 51():397-418. PubMed ID: 21210747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV latency in the humanized BLT mouse.
    Marsden MD; Kovochich M; Suree N; Shimizu S; Mehta R; Cortado R; Bristol G; An DS; Zack JA
    J Virol; 2012 Jan; 86(1):339-47. PubMed ID: 22072769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Latent Reservoir for HIV-1.
    Sengupta S; Siliciano RF
    Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
    Katlama C; Deeks SG; Autran B; Martinez-Picado J; van Lunzen J; Rouzioux C; Miller M; Vella S; Schmitz JE; Ahlers J; Richman DD; Sekaly RP
    Lancet; 2013 Jun; 381(9883):2109-17. PubMed ID: 23541541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical Models of HIV Latency.
    Hill AL
    Curr Top Microbiol Immunol; 2018; 417():131-156. PubMed ID: 29164341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
    Shan L; Siliciano RF
    Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.
    Reeves DB; Duke ER; Wagner TA; Palmer SE; Spivak AM; Schiffer JT
    Nat Commun; 2018 Nov; 9(1):4811. PubMed ID: 30446650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
    Forde J; Volpe JM; Ciupe SM
    Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective BCL-X
    Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
    J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.
    Laird GM; Rosenbloom DI; Lai J; Siliciano RF; Siliciano JD
    Methods Mol Biol; 2016; 1354():239-53. PubMed ID: 26714716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A broad drug arsenal to attack a strenuous latent HIV reservoir.
    Stoszko M; Ne E; Abner E; Mahmoudi T
    Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1
    Llewellyn GN; Seclén E; Wietgrefe S; Liu S; Chateau M; Pei H; Perkey K; Marsden MD; Hinkley SJ; Paschon DE; Holmes MC; Zack JA; Louie SG; Haase AT; Cannon PM
    J Virol; 2019 May; 93(10):. PubMed ID: 30842333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
    Sluis-Cremer N
    Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.